(GBLB) Groep Brussel Lambert - Ratings and Ratios
Industrial, Consumer Goods, Business Services, Investments
GBLB EPS (Earnings per Share)
GBLB Revenue
Description: GBLB Groep Brussel Lambert
Groupe Bruxelles Lambert SA is a multi-sector holding company with a diverse portfolio of investments in industrial, consumer goods, and business service companies across various regions, including Europe, North America, and internationally. The companys operations are segmented into six key areas: Holding, Imerys, Canyon, Affidea, Sanoptis, and GBL Capital and Sienna Investment Managers.
To further analyze GBLBs performance, we can examine key performance indicators (KPIs) such as dividend yield, return on equity (ROE), and debt-to-equity ratio. A review of the companys financials reveals a ROE of 0.21, indicating a relatively low return on shareholder equity. Additionally, the companys market capitalization stands at approximately €9.033 billion, suggesting a significant presence in the market.
From a valuation perspective, GBLBs price-to-earnings (P/E) ratio is 306.04, which may indicate that the stock is overvalued. However, without a forward P/E ratio, its challenging to determine the companys growth prospects. To gain a more comprehensive understanding of GBLBs valuation, we can consider other metrics, such as the price-to-book (P/B) ratio or enterprise value-to-EBITDA (EV/EBITDA) ratio.
To make an informed investment decision, its essential to evaluate GBLBs underlying assets and their respective performances. For instance, Imerys, one of GBLBs key investments, is a world leader in mineral-based solutions for industrial applications. Analyzing the financial performance and growth prospects of such assets can provide valuable insights into GBLBs overall potential.
GBLB Stock Overview
| Market Cap in USD | 10,835m |
| Sub-Industry | Multi-Sector Holdings |
| IPO / Inception |
GBLB Stock Ratings
| Growth Rating | 24.1% |
| Fundamental | 49.8% |
| Dividend Rating | 65.9% |
| Return 12m vs S&P 500 | -0.37% |
| Analyst Rating | - |
GBLB Dividends
| Dividend Yield 12m | 7.17% |
| Yield on Cost 5y | 7.91% |
| Annual Growth 5y | -2.68% |
| Payout Consistency | 98.6% |
| Payout Ratio | 3.1% |
GBLB Growth Ratios
| Growth Correlation 3m | 76.7% |
| Growth Correlation 12m | 74.9% |
| Growth Correlation 5y | -46% |
| CAGR 5y | 3.44% |
| CAGR/Max DD 5y | 0.10 |
| Sharpe Ratio 12m | 1.92 |
| Alpha | 9.35 |
| Beta | 0.300 |
| Volatility | 13.52% |
| Current Volume | 131.2k |
| Average Volume 20d | 66k |
| Stop Loss | 72.8 (-3.1%) |
| Signal | -2.16 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (-102.7m TTM) > 0 and > 6% of Revenue (6% = 365.3m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA 0.98pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 44.97% (prev 31.29%; Δ 13.68pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 1.21b > Net Income -102.7m (YES >=105%, WARN >=100%) |
| Net Debt (5.79b) to EBITDA (908.4m) ratio: 6.37 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.91 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (130.3m) change vs 12m ago -4.24% (target <= -2.0% for YES) |
| Gross Margin 51.04% (prev 48.22%; Δ 2.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 22.85% (prev 29.52%; Δ -6.67pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.88 (EBITDA TTM 908.4m / Interest Expense TTM 396.9m) >= 6 (WARN >= 3) |
Altman Z'' 2.55
| (A) 0.11 = (Total Current Assets 5.73b - Total Current Liabilities 3.00b) / Total Assets 25.54b |
| (B) 0.30 = Retained Earnings (Balance) 7.70b / Total Assets 25.54b |
| (C) 0.01 = EBIT TTM 350.5m / Avg Total Assets 26.64b |
| (D) 0.74 = Book Value of Equity 8.27b / Total Liabilities 11.24b |
| Total Rating: 2.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 49.76
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 4.63% = 2.32 |
| 3. FCF Margin 9.67% = 2.42 |
| 4. Debt/Equity 0.55 = 2.35 |
| 5. Debt/Ebitda 7.46 = -2.50 |
| 6. ROIC - WACC -4.42% = -5.53 |
| 7. RoE -0.70% = -0.12 |
| 8. Rev. Trend -28.15% = -1.41 |
| 9. Rev. CAGR 2.91% = 0.36 |
| 10. EPS Trend -5.41% = -0.14 |
| 11. EPS CAGR 38.04% = 2.50 |
What is the price of GBLB shares?
Over the past week, the price has changed by -2.09%, over one month by -1.12%, over three months by +4.31% and over the past year by +16.54%.
Is Groep Brussel Lambert a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GBLB is around 77.71 EUR . This means that GBLB is currently overvalued and has a potential downside of 3.48%.
Is GBLB a buy, sell or hold?
What are the forecasts/targets for the GBLB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 86 | 14.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 84 | 11.9% |
GBLB Fundamental Data Overview
Market Cap EUR = 9.30b (9.30b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 3.37b EUR (Cash And Short Term Investments, last quarter)
P/S = 1.4381
P/B = 0.7523
Beta = 0.756
Revenue TTM = 6.09b EUR
EBIT TTM = 350.5m EUR
EBITDA TTM = 908.4m EUR
Long Term Debt = 5.62b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.16b EUR (from shortTermDebt, last quarter)
Debt = 6.78b EUR (Calculated: Short Term 1.16b + Long Term 5.62b)
Net Debt = 5.79b EUR (from netDebt column, last quarter)
Enterprise Value = 12.71b EUR (9.30b + Debt 6.78b - CCE 3.37b)
Interest Coverage Ratio = 0.88 (Ebit TTM 350.5m / Interest Expense TTM 396.9m)
FCF Yield = 4.63% (FCF TTM 589.0m / Enterprise Value 12.71b)
FCF Margin = 9.67% (FCF TTM 589.0m / Revenue TTM 6.09b)
Net Margin = -1.69% (Net Income TTM -102.7m / Revenue TTM 6.09b)
Gross Margin = 51.04% ((Revenue TTM 6.09b - Cost of Revenue TTM 2.98b) / Revenue TTM)
Tobins Q-Ratio = 1.54 (Enterprise Value 12.71b / Book Value Of Equity 8.27b)
Interest Expense / Debt = 5.85% (Interest Expense 396.9m / Debt 6.78b)
Taxrate = 59.23% (from yearly Income Tax Expense: 91.8m / 155.0m)
NOPAT = 142.9m (EBIT 350.5m * (1 - 59.23%))
Current Ratio = 1.91 (Total Current Assets 5.73b / Total Current Liabilities 3.00b)
Debt / Equity = 0.55 (Debt 6.78b / last Quarter total Stockholder Equity 12.36b)
Debt / EBITDA = 7.46 (Net Debt 5.79b / EBITDA 908.4m)
Debt / FCF = 11.51 (Debt 6.78b / FCF TTM 589.0m)
Total Stockholder Equity = 14.71b (last 4 quarters mean)
RoA = -0.40% (Net Income -102.7m, Total Assets 25.54b )
RoE = -0.70% (Net Income TTM -102.7m / Total Stockholder Equity 14.71b)
RoCE = 1.72% (Ebit 350.5m / (Equity 14.71b + L.T.Debt 5.62b))
RoIC = 0.70% (NOPAT 142.9m / Invested Capital 20.36b)
WACC = 5.12% (E(9.30b)/V(16.08b) * Re(7.12%)) + (D(6.78b)/V(16.08b) * Rd(5.85%) * (1-Tc(0.59)))
Shares Correlation 5-Years: -80.0 | Cagr: -3.04%
Discount Rate = 7.12% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 79.56% ; FCFE base≈500.6m ; Y1≈548.4m ; Y5≈698.2m
Fair Price DCF = 99.29 (DCF Value 12.15b / Shares Outstanding 122.4m; 5y FCF grow 10.90% → 3.0% )
Revenue Correlation: -28.15 | Revenue CAGR: 2.91%
Rev Growth-of-Growth: -19.54
EPS Correlation: -5.41 | EPS CAGR: 38.04%
EPS Growth-of-Growth: -227.3